Trial
NCT02267707
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Pancreatic Neoplasms
Intervention
nab-paclitaxel
Why stopped
Study population more infrequent than estimated. No study-related safety issues and no safety concerns were identified for the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-01